.

Name : Ms. M SAMRAJYAM

Lab No. : 386312169 Age : 46 Years
Ref By : SELF Gender : Female
Collected : 20/3/2023 12:04:00PM Reported : 22/3/2023 11:39:31AM
A/c Status : P Report Status : Final
Collected at : AAROGYA CARE DIAGNOS Processed at : LPL-BENGALURU REFERENCE LAB
NO.17/1,SERVICE ROAD, THE ADDRESS,OPP
PRESTIGE CESSNA PARK, OUTER RING
ROAD ,KADUBEESANAHALLI
,BANGALORE-560103

Test Report

Test Name Results Units Bio. Ref. Interval

HOMA IR;INSULIN RESISTANCE INDEX, C- PEPTIDE MODEL

C-peptide, Serum, Fasting 5.63 ng/mL 0.81 - 3.85

Beta Cell Function (%B) 50.50 %

Insulin Sensitivity (%S) 16.00 %

HOMA IR Index 6.25 <2.50

Comment
Homeostatic model assessment (HOMA) is a method for assessing beta cell function (%B) and insulin
sensitivity (%S) from fasting glucose and C-peptide concentrations. HOMA can be used to track changes in
insulin sensitivity and beta cell function to examine natural history of diabetes. Insulin sensitivity is reduced in
normal subjects having first degree relative with type 2 diabetes compared with control subjects. Changes in
beta cell sensitivity in subjects on insulin secretogogues may be useful in determining beta cell function over a
period.

Usage
To assess response to treatment in diabetics taking exogenous insulin.

DR HARISH K Dr Richa Daljeet Singh

MBBS,DCP MD,Pathology
Chief of Laboratory Chief of Laboratory
Dr Lal PathLabs Ltd Dr Lal PathLabs Ltd

*386312169*
Page 1 of 6
.

Name : Ms. M SAMRAJYAM

Lab No. : 386312169 Age : 46 Years
Ref By : SELF Gender : Female
Collected : 20/3/2023 12:04:00PM Reported : 22/3/2023 11:39:31AM
A/c Status : P Report Status : Final
Collected at : AAROGYA CARE DIAGNOS Processed at : LPL-HYDERABAD
4th Floor, Oyster Oasis Centre, MCH No.
6-3-1112 Greenland’s Road Somajiguda,
Circle no. 10, Old MCH Circle no. 5,GHMC,
Begumpet, Hyderabad -500016

Test Report

Test Name Results Units Bio. Ref. Interval

HOMA IR;INSULIN RESISTANCE INDEX, C- PEPTIDE MODEL

Glucose Plasma, Fasting 209.50 mg/dL 70.00 - 100.00

Comment
Homeostatic model assessment (HOMA) is a method for assessing beta cell function (%B) and insulin
sensitivity (%S) from fasting glucose and C-peptide concentrations. HOMA can be used to track changes in
insulin sensitivity and beta cell function to examine natural history of diabetes. Insulin sensitivity is reduced in
normal subjects having first degree relative with type 2 diabetes compared with control subjects. Changes in
beta cell sensitivity in subjects on insulin secretogogues may be useful in determining beta cell function over a
period.

Usage
To assess response to treatment in diabetics taking exogenous insulin.

*386312169*
Page 2 of 6
.

Name : Ms. M SAMRAJYAM

Lab No. : 386312169 Age : 46 Years
Ref By : SELF Gender : Female
Collected : 20/3/2023 12:04:00PM Reported : 22/3/2023 11:39:31AM
A/c Status : P Report Status : Final
Collected at : AAROGYA CARE DIAGNOS Processed at : LPL-HYDERABAD
4th Floor, Oyster Oasis Centre, MCH No.
6-3-1112 Greenland’s Road Somajiguda,
Circle no. 10, Old MCH Circle no. 5,GHMC,
Begumpet, Hyderabad -500016

Test Report

Test Name Results Units Bio. Ref. Interval

HbA1c (GLYCOSYLATED HEMOGLOBIN), BLOOD
(HPLC, NGSP certified)

HbA1c 9.6 % 4.00 - 5.60

Estimated average glucose (eAG) 229 mg/dL

Interpretation
HbA1c result is suggestive of Diabetes/ Higher than glycemic goal in a known Diabetic patient.

Please note, Glycemic goal should be individualized based on duration of diabetes, age/life expectancy,
comorbid conditions, known CVD or advanced microvascular complications, hypoglycaemia unawareness,
and individual patient considerations

Result Rechecked,
Please Correlate Clinically.

Note: Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered,
particularly when the HbA1C result does not correlate with the patient’s blood glucose levels.

---------------------------------------------------------------------------------
| FACTORS THAT INTERFERE WITH HbA1C | FACTORS THAT AFFECT INTERPRETATION |
| MEASUREMENT | OF HBA1C RESULTS |
|--------------------------------------|------------------------------------------|
| Hemoglobin variants,elevated fetal | Any condition that shortens erythrocyte |
| hemoglobin (HbF) and chemically | survival or decreases mean erythrocyte |
| modified derivatives of hemoglobin | age (e.g.,recovery from acute blood loss,|
| (e.g. carbamylated Hb in patients | hemolytic anemia, HbSS, HbCC, and HbSC) |
| with renal failure) can affect the | will falsely lower HbA1c test results |
| accuracy of HbA1c measurements | regardless of the assay method used.Iron |
| | deficiency anemia is associated with |
| | higher HbA1c |
---------------------------------------------------------------------------------

*386312169* Page 3 of 6
.

Name : Ms. M SAMRAJYAM

Lab No. : 386312169 Age : 46 Years
Ref By : SELF Gender : Female
Collected : 20/3/2023 12:04:00PM Reported : 22/3/2023 11:39:31AM
A/c Status : P Report Status : Final
Collected at : AAROGYA CARE DIAGNOS Processed at : LPL-HYDERABAD
4th Floor, Oyster Oasis Centre, MCH No.
6-3-1112 Greenland’s Road Somajiguda,
Circle no. 10, Old MCH Circle no. 5,GHMC,
Begumpet, Hyderabad -500016

Test Report

Test Name Results Units Bio. Ref. Interval

GLUCOSE, POST PRANDIAL (PP), 2 HOURS, 259.68 mg/dL 70.00 - 140.00

PLASMA
(Hexokinase)

PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

*386312169*
Page 4 of 6
.

Name : Ms. M SAMRAJYAM

Lab No. : 386312169 Age : 46 Years
Ref By : SELF Gender : Female
Collected : 20/3/2023 12:04:00PM Reported : 22/3/2023 11:39:31AM
A/c Status : P Report Status : Final
Collected at : AAROGYA CARE DIAGNOS Processed at : LPL-HYDERABAD
4th Floor, Oyster Oasis Centre, MCH No.
6-3-1112 Greenland’s Road Somajiguda,
Circle no. 10, Old MCH Circle no. 5,GHMC,
Begumpet, Hyderabad -500016

Test Report

Test Name Results Units Bio. Ref. Interval

INSULIN, FASTING, SERUM 58.84 µU/mL 2.60 - 24.90

(ECLIA)

Note
1. A single random blood sample for insulin may provide insufficient information due to wide variation in
the time responses of insulin levels and blood glucose.
2. Stimulation of insulin secretion may be caused by many factors like hyperglycemia, glucagon, amino
acids, growth hormone and catecholamines.
3. Interference in insulin assay is seen due to insulin antibodies which develop in patients treated with
bovine or porcine insulin.

Clinical Utility
· Evaluation of fasting hypoglycemia
· Evaluation of Polycystic Ovary syndrome
· Classification of Diabetes mellitus
· Predict Diabetes mellitus
· Assessment of Beta cell activity
· Select optimal therapy for Diabetes
· Investigation of insulin resistance
· Predict the development of Coronary Artery Disease

Increased levels - Insulinoma, Some Type II diabetic patients, Infantile hypoglycemia, Hyperinsulinism,
Obesity, Cushing's syndrome, Oral contraceptives, Acromegaly, Hyperthyroidism

Decreased levels - Untreated Type I Diabetes mellitus

Dr Mattaparti Sridevi Dr Syeda Iqra Taskeen

MD, Pathology
Chief of Laboratory Consultant Pathologist
Dr Lal PathLabs Ltd Dr Lal PathLabs Ltd

-------------------------------End of report --------------------------------

PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

*386312169*
Page 5 of 6
.

Name : Ms. M SAMRAJYAM

Lab No. : 386312169 Age : 46 Years
Ref By : SELF Gender : Female
Collected : 20/3/2023 12:04:00PM Reported : 22/3/2023 11:39:31AM
A/c Status : P Report Status : Final
Collected at : AAROGYA CARE DIAGNOS Processed at : LPL-HYDERABAD
4th Floor, Oyster Oasis Centre, MCH No.
6-3-1112 Greenland’s Road Somajiguda,
Circle no. 10, Old MCH Circle no. 5,GHMC,
Begumpet, Hyderabad -500016

Test Report

Test Name Results Units Bio. Ref. Interval

AHEEEHAPMKHLBKBNLHFKCJNCBILLJCECCIJCIOPHNKEDFFFAPPAHEEEHA
BNFFFNBPAPBOMPAGFOEHNGAPAOAHFHAKAONOBCJCJLELMCJGMPBNFFFNB
CMDBAHFNJMMIMPLKMFIAAJHFJAFEHEDHPKPHENFLMKKIKEFLBKHDEHANP
DJJGHKFNBJEIEHIENIMELHNFANHKBLBFJIFFPAPAKEDJPDNLIJFBKEMEK
IDGMDFFIPJNFDIALDFPBODJEIENLIDCHKKMHGGEIOLKGKPNGKFFFOOKEG
JECBBEFBLIOPBJHKIBPJLIPBADHFOFAINCFCBKDNKLIKOMNALNEIOOECL
ODIMIJFBALOHABOIECIEJEFHIHAFJBAKPPEPBLMGOJCHKLNKIJNJIDILD
JNLFAMFMAKMBADPKDANHDOPILLBMFMBFIFCCAMNNIJKFMPNOBNFMBHILL
NKABDDFJPMCGFAEDIMPIHCNKHMAFEKFBJFFKBKPFOCLIOCNKDJPHNEKLJ
PNIEABFCEMJJJDCIKKDCNHBPKDFKPNJHKEPHEFNLMKCKIGEOCMLKHJENK
HJIKAIFLGKCPDMBMPHAHCJEEINMFFJABJNFEBFOHPNDMKOEKEPCIGKIMO
AGICGJFNFLDIBKGMHPOFENDEIEOPPFOFBOPPBLNOOLJBJONINKONHDICL
MNNNNNEHCHAFKDGNHCFLHOEHJBAHFHAFLKPFCMNLMKIELFNLAHFHAHIKL
APBBBPAPBFCAENBNJPCKCJLFAEGCHHCAONFFPLPGOPCHNLNFEDFFDBKHH
HHHHHHHPHPHPHPPHHPPHPHHHPHPPPPPPPPPHHPHPPHHHPHPHHHHPPHPHP

IMPORTANT INSTRUCTIONS
ŸTest results released pertain to the specimen submitted .ŸAll test results are dependent on the quality of the sample received by the Laboratory .
ŸLaboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .ŸReport
delivery may be delayed due to unforeseen circumstances. Inconvenience is regretted .ŸCertain tests may require further testing at additional cost for
derivation of exact value. Kindly submit request within 72 hours post reporting.ŸTest results may show interlaboratory variations .ŸThe Courts/Forum
at Delhi shall have exclusive jurisdiction in all disputes /claims concerning the test(s) & or results of test(s).ŸTest results are not valid for medico legal
purposes.ŸThis is computer generated medical diagnostic report that has been validated by Authorized Medical Practitioner /Doctor.ŸThe report does
not need physical signature.
(#) Sample drawn from outside source.
If Test results are alarming or unexpected, client is advised to contact the Customer Care immediately for possible remedial action.
Tel: +91-11-49885050,Fax: - +91-11-2788-2134, E-mail: lalpathlabs@lalpathlabs.com

PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

*386312169*
Page 6 of 6